Fezolinetant: A Promising New Non-hormonal Drug Against Menopausal Symptoms

During menopause, up to 80% of individuals experience vasomotor symptoms, such as hot flashes, that severely impact quality of life. Fezolinetant is a novel oral drug that shows promise in treating hot flashes by acting as a neurokinin 3 receptor antagonist that restores hypothalamic thermoregulation. This review explores the effectiveness of Fezolinetant in reducing menopausal symptoms compared to the current pharmacological standard of care. We evaluate the strengths of Fezolinetant as an alternative treatment for patients that are eligible for traditional hormone replacement therapy and outline current limitations of the medication. The potential benefits of Fezolinetant warrant further research and post-market clinical trials to continue monitoring its efficacy and safety.

Authors

Publication Details

Journal
The Meducator
Published
2025-02-22
DOI
https://doi.org/10.15173/m.v1i45.3689
Primary Topic
Estrogen and related hormone effects
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Fezolinetant: A Promising New Non-hormonal Drug Against Menopausal Symptoms

The Meducator, Anh Dzung Nguyen, Zhengyi Chen
The Meducator
Estrogen and related hormone effects
article

Fezolinetant: A Promising New Non-hormonal Drug Against Menopausal Symptoms

The Meducator, Anh Dzung Nguyen, Zhengyi Chen
article en

Abstract

During menopause, up to 80% of individuals experience vasomotor symptoms, such as hot flashes, that severely impact quality of life. Fezolinetant is a novel oral drug that shows promise in treating hot flashes by acting as a neurokinin 3 receptor antagonist that restores hypothalamic thermoregulation. This review explores the effectiveness of Fezolinetant in reducing menopausal symptoms compared to the current pharmacological standard of care. We evaluate the strengths of Fezolinetant as an alternative treatment for patients that are eligible for traditional hormone replacement therapy and outline current limitations of the medication. The potential benefits of Fezolinetant warrant further research and post-market clinical trials to continue monitoring its efficacy and safety.

The MeducatorVol. 1(45)
Openalex Percentile: Top 96%
Estrogen and related hormone effects
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.